Seattle Genetics (NASDAQ: [[ticker:SGEN]]) said today that the FDA has agreed to provide a faster-than-usual six-month review of its application to start selling brentuximab vedotin (SGN-35) for the treatment of patients with Hodgkin’s disease and anaplastic large cell lymphoma. The agency now has until August 30 to decide whether the drug is ready for sale in the U.S. The FDA usually takes 10 months to review new drug applications, but it sometimes speeds up the process for potentially groundbreaking or lifesaving new therapies.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
